Skip to main content
SpringerLink
Log in

Platelet microparticles and platelet adhesion: Therapeutic implications for the prevention and treatment of stroke

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Platelets are believed to play a part in all stages of the pathogenesis of ischemic stroke, from the initial formation of the atherosclerotic plaque, through plaque destabilization to the development of neuronal cell death. A process common to all of these pathogenic changes is the ability of the activated platelet to adhere to the site of disease. In addition, the release of the membrane vesicles from platelets enhances many of these processes. Therefore, an understanding of platelet adhesion and platelet microparticle release can aid the development toward the treatment and prevention of stroke. There has been much research into interventions that can reduce platelet activation in atherosclerosis and stroke. The benefits of nonpharmacologic interventions in stroke, such as diet and lifestyle modification, may in part be mediated by their effects on platelet activation. In addition, the antiplatelet drug aspirin has been shown to be useful in both the treatment of acute stroke and the secondary prevention of atherothrombosis. Other antiplatelet agents, such as the glycoprotein IIb/IIIa inhibitors and triflusal, are currently being evaluated for the treatment of acute atherothrombotic stroke.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. van Gijn J: Stroke: cerebrovascular disease. In Oxford Textbook of Medicine. Edited by Warrell D, et al. Oxford: Oxford University Press; 2004:24.13.07.00. Excellent up-to-date review of the clinical aspects of stroke.

    Google Scholar 

  2. Massberg S, Brand K, Gruner S, et al.: A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002, 196:887–896.

    Article  PubMed  CAS  Google Scholar 

  3. Hynes RO: Integrins: Versatility, modulation, and signalling in cell adhesion. Cell 1992, 69:11–25.

    Article  PubMed  CAS  Google Scholar 

  4. von Hundelshausen P, Weber KS, Huo Y, et al.: RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001, 103:1772–1777.

    Google Scholar 

  5. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115–126.

    Article  PubMed  CAS  Google Scholar 

  6. Hawrylowicz CM, Howells GL, Feldmann M: Plateletderived interleukin-1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 1991, 174:785–790.

    Article  PubMed  CAS  Google Scholar 

  7. Phipps RP: Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 2000, 97:6930–6932.

    Article  PubMed  CAS  Google Scholar 

  8. Larsen E, Celi A, Gilbert GE, et al.: PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989, 59:305–312.

    Article  PubMed  CAS  Google Scholar 

  9. McEver RP, Cummings RD: Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997, 100:485–492.

    PubMed  CAS  Google Scholar 

  10. Huo Y, Schober A, Forlow SB, et al.: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003, 9:61–67. This is one of the first studies illustrating the importance of activated platelets in the formation of the atherosclerotic plaque. Essential reading for anyone interested in understanding how activated platelets affect plaque formation.

    Article  PubMed  CAS  Google Scholar 

  11. Schonbeck U, Libby P: CD40 signalling and plaque instability. Circ Res 2001, 89:1092–1103.

    PubMed  CAS  Google Scholar 

  12. Tan KT, Lip GY: Red vs white thrombi: treating the right clot is crucial. Arch Intern Med 2003, 163:2534–2535.

    Article  PubMed  CAS  Google Scholar 

  13. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22:391–397.

    Article  PubMed  CAS  Google Scholar 

  14. Small DL, Morley P, Buchan AM: Biology of ischemic cerebral cell death. Prog Cardiovasc Dis 1999, 42:185–207.

    Article  PubMed  CAS  Google Scholar 

  15. Tan KT, Lip GY, Blann AD: Post-stroke inflammatory response: effects on stroke evolution and outcome. Curr Atheroscler Rep 2003, 5:245–251. Recent review on the mechanisms by which poststroke inflammation can affect outcome.

    Article  PubMed  Google Scholar 

  16. Bednar MM, Raymond S, McAullife T, et al.: The role of neutrophils and platelets in a rabbit model of thromboembolic stroke. Stroke 1991, 22:44–50.

    PubMed  CAS  Google Scholar 

  17. del Zoppo GJ, Schmid-Schonbein GW, Mori E, et al.: Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991, 22:1276–1283.

    PubMed  Google Scholar 

  18. Sughrue ME, Mehra A, Connolly ES, D’Ambrosia AL: Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischaemia: a critical review of the literature. Inflamm Res 2004, 53:497–508.

    Article  PubMed  CAS  Google Scholar 

  19. Choudhri TF, Hoh BL, Zerwes HG, et al.: Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GPIIb/IIIa receptormediated platelet aggregation. J Clin Invest 1998, 102:1301–1310.

    PubMed  CAS  Google Scholar 

  20. Faraday N, Scharpf RB, Dodd-o JM, et al.: Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand-1 with P-selectin. Anesthesiology 2001, 94:145–151.

    Article  PubMed  CAS  Google Scholar 

  21. Weyrich AS, Elstad MR, McEver RP, et al.: Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996, 97:1525–1534.

    Article  PubMed  CAS  Google Scholar 

  22. Nagata K, Tsuji T, Todoroki N, et al.: Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin. J Immunol 1993, 151:3267–3273.

    PubMed  CAS  Google Scholar 

  23. Zwaal RF, Schroit AJ: Pathophysiological implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121–1132.

    PubMed  CAS  Google Scholar 

  24. Yano Y, Kambayashi J, Shiba E, et al.: The role of protein phosphorylation and cytoskeletal reorganisation in microparticle formation from the platelet plasma membrane. Biochem J 1994, 299:303–308.

    PubMed  CAS  Google Scholar 

  25. Tan KT, Tayebjee MH, Lynd C, et al.: Platelet microparticles and soluble P-selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 2005, 37:1–6.

    Google Scholar 

  26. Podor TJ, Singh D, Chindemi P, et al.: Vimentin exposed on activated platelets and platelet microparticles localises vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002, 277:7529–7539.

    Article  PubMed  CAS  Google Scholar 

  27. Salonen EM, Vaheri A, Pollanen J, et al.: Interaction of plasminogen activator inhibitor with vitronectin. J Biol Chem 1989, 264:6339–6343.

    PubMed  CAS  Google Scholar 

  28. Zhang ZG, Chopp M, Goussev A, et al.: Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischaemia in rats. J Neurosci 1999, 19:10898–10907.

    PubMed  CAS  Google Scholar 

  29. Nagai N, Suzuki Y, Van Hoef B, et al.: Effects of plasminogen activator inhibitor-1 on ischaemic brain injury in permanent and thrombotic middle cerebral artery occlusion in mice. J Thromb Haemost 2005, 3:1379–1384.

    Article  PubMed  CAS  Google Scholar 

  30. Merten M, Pakala R, Thiagarajan P, Benedict CR: Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation 1999, 99:2577–2582.

    PubMed  CAS  Google Scholar 

  31. Barry OP, Pratico D, Lawson JA, Fitzgerald GA: Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997, 99:2118–2127.

    PubMed  CAS  Google Scholar 

  32. Barry OP, Pratico D, Savani RC, Fitzgerald GA: Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998, 102:136–144.

    PubMed  CAS  Google Scholar 

  33. Jy W, Mao WW, Horstman L, et al.: Platelet microparticles bind, activate, and aggregate neutrophils in vitro. Blood Cells Mol Dis 1995, 21:217–231.

    Article  PubMed  CAS  Google Scholar 

  34. Levine PH: An acute effect of cigarette smoking on platelet function. A possible link between smoking and arterial thrombosis. Circulation 1973, 48:619–623.

    PubMed  CAS  Google Scholar 

  35. Hawkins RI: Smoking, platelets and thrombosis. Nature 1972, 236:450–452.

    Article  PubMed  CAS  Google Scholar 

  36. Carlsson I, Wennmalm A: Platelet aggregability in smoking and non-smoking subjects. Clin Physiol 1983, 3:565–571.

    PubMed  CAS  Google Scholar 

  37. Wennmalm A, Benthin G, Granstrom L, et al.: Maintained hyperexcretion of thromboxane A2 metabolite in healthy young cigarette smokers. Clin Physiol 1993, 13:257–264.

    PubMed  CAS  Google Scholar 

  38. Pernerstorfer T, Stohlawetz P, Stummvoll G, et al.: Lowdose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haematol 1998, 102:1229–1231.

    Article  PubMed  CAS  Google Scholar 

  39. Feng DL, Murillo J, Jadhav P, et al.: Upright posture and maximal exercise increase platelet aggregability and prostacyclin production in healthy male subjects. Br J Sports Med 1999, 33:401–404.

    Article  PubMed  CAS  Google Scholar 

  40. Coppola L, Grassia A, Coppola A, et al.: Effects of moderate intensity aerobic program on blood viscosity, platelet aggregation and fibrinolytic balance in young and middle aged sedentary subjects. Blood Coagul Fibrinolysis 2004, 15:31–37.

    Article  PubMed  CAS  Google Scholar 

  41. Durand P, Prost M, Blache D: Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996, 121:231–243.

    Article  PubMed  CAS  Google Scholar 

  42. Graham IM, Daly L, Refsum H, et al.: Plasma homocysteine as a risk factor for vascular disease. JAMA 1997, 277:1775–1781.

    Article  PubMed  CAS  Google Scholar 

  43. Toole JF, Malinow R, Chambless LE, et al.: Lowering homocysteine in patients with ischaemic stroke to prevent recurrent stroke, myocardial infarction and death. JAMA 2004, 291:565–575.

    Article  PubMed  CAS  Google Scholar 

  44. Steiner M, Anastasi J: Vitamin E. An inhibitor of the platelet release reaction. J Clin Invest 1976, 57:732–737.

    PubMed  CAS  Google Scholar 

  45. Calzada C, Bruckdorfer KR, Rice-Evans CA: The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 1997, 128:97–105.

    Article  PubMed  CAS  Google Scholar 

  46. Stephens NG, Parsons A, Schofield PM, et al.: Randomised controlled trial of vitamin E in patients with coronary heart disease: Cambridge Heart Antioxidant Study. Lancet 1996, 347:781–786.

    Article  PubMed  CAS  Google Scholar 

  47. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.

    Article  PubMed  CAS  Google Scholar 

  48. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23–33.

    Article  Google Scholar 

  49. Wilkinson IB, Megson IL, MacCallum H, et al.: Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. J Cardiovasc Pharmacol 1999, 34:690–693.

    Article  PubMed  CAS  Google Scholar 

  50. Needleman P, Raz A, Minkes MS, et al.: Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A 1979, 76:944–948.

    Article  PubMed  CAS  Google Scholar 

  51. Renaud SC, Ruf JC: Effects of alcohol on platelet function. Clin Chim Acta 1996, 246:77–89.

    Article  PubMed  CAS  Google Scholar 

  52. Fremont L: Biological effects of resveratrol. Life Sci 2000, 66:663–673.

    Article  PubMed  CAS  Google Scholar 

  53. Varani K, Portaluppi F, Gessi S, et al.: Dose and time effects of caffeine intake on human platelet adenosine A2a receptors. Circulation 2000, 102:285–289.

    PubMed  CAS  Google Scholar 

  54. Musselman DL, Marzec UM, Manatunga A, et al.: Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000, 57:875–882.

    Article  PubMed  CAS  Google Scholar 

  55. Chen ZM, Sandercock P, Pan HC, et al.: Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40000 randomised patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000, 31:1240–1249.

    PubMed  CAS  Google Scholar 

  56. Collaborative overview of randomised trials of antiplatelet therapy—1. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration [no authors listed]. BMJ 1994, 308:81–106.

  57. Junghans U, Seitz RJ, Ritzl A, et al.: Ischaemic brain tissue salvaged from infarction by the GPIIb/IIIa platelet antagonist tirofiban. Neurology 2002, 58:474–476.

    PubMed  CAS  Google Scholar 

  58. A randomised, blinded, trial of clopidogrel over aspirin in patients at risk of ischaemic events. CAPRIE Steering Committee [no authors listed]. Lancet 1996, 348:1329–1339.

  59. Diener HC, Bogousslavsky J, Brass LM, et al.: Aspirin and clopidogrel compared to clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high risk patients (MATCH). Lancet 2004, 364:331–337.

    Article  PubMed  CAS  Google Scholar 

  60. De Miguel LS, Jimenez A, Monton M, et al.: A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function. Eur J Clin Invest 2000, 30:811–817.

    Article  PubMed  Google Scholar 

  61. Acarin K, Gonzalez B, Castellano B: Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic damage. Stroke 2002, 33:2499–2505.

    Article  PubMed  CAS  Google Scholar 

  62. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, et al.: Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. Stroke 2003, 34:840–848.

    Article  PubMed  CAS  Google Scholar 

  63. Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1–13.

    Article  PubMed  CAS  Google Scholar 

  64. Sacco RL, Sivenius J, Diener HC: Efficacy of aspirin plus extended release dipyridamole in preventing recurrent stroke in high risk populations. Arch Neurol 2005, 62:403–408. Interesting study that suggests that an aspirin/dipyridamole combination may be more efficacious at preventing stroke than aspirin alone.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine City Hospital, Dudley Road, B18 7QH, Birmingham, UK

    Gregory Y. H. Lip MD, FRCP

Authors
  1. Kiat T. Tan MD, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Y. H. Lip MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tan, K.T., Lip, G.Y.H. Platelet microparticles and platelet adhesion: Therapeutic implications for the prevention and treatment of stroke. Curr Treat Options Cardio Med 8, 251–258 (2006). https://doi.org/10.1007/s11936-006-0019-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-006-0019-5

Keywords

Search

Navigation